These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34389159)

  • 1. Circulating tumour DNA for clinicians: current and future clinical applications.
    Thompson MK; Gale D; Brenton JD
    Clin Radiol; 2021 Oct; 76(10):737-747. PubMed ID: 34389159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
    Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T
    Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection.
    Fiala C; Diamandis EP
    BMC Med; 2018 Oct; 16(1):166. PubMed ID: 30285732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA methylation: a promising clinical tool for cancer diagnosis and management.
    Wang B; Wang M; Lin Y; Zhao J; Gu H; Li X
    Clin Chem Lab Med; 2024 Oct; 62(11):2111-2127. PubMed ID: 38443752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
    Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
    CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
    Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
    Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent Advancements in the Application of Circulating Tumor DNA as Biomarkers for Early Detection of Cancers.
    Mishra M; Ahmed R; Das DK; Pramanik DD; Dash SK; Pramanik A
    ACS Biomater Sci Eng; 2024 Aug; 10(8):4740-4756. PubMed ID: 38950521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.
    Cree IA; Uttley L; Buckley Woods H; Kikuchi H; Reiman A; Harnan S; Whiteman BL; Philips ST; Messenger M; Cox A; Teare D; Sheils O; Shaw J;
    BMC Cancer; 2017 Oct; 17(1):697. PubMed ID: 29061138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
    Chen M; Zhao H
    Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.
    Batth IS; Mitra A; Manier S; Ghobrial IM; Menter D; Kopetz S; Li S
    Ann Oncol; 2017 Mar; 28(3):468-477. PubMed ID: 27998963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.
    Guan Y; Mayba O; Sandmann T; Lu S; Choi Y; Darbonne WC; Leveque V; Ryner L; Humke E; Tam NWR; Sujathasarma S; Cheung A; Bourgon R; Lackner MR; Wang Y
    J Mol Diagn; 2017 Nov; 19(6):921-932. PubMed ID: 28867605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
    Croessmann S; Park BH
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
    Naidoo M; Piercey O; Tie J
    Curr Oncol Rep; 2021 Nov; 23(12):140. PubMed ID: 34735665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
    Fiala C; Diamandis EP
    Clin Chem Lab Med; 2020 Sep; 58(10):1651-1653. PubMed ID: 32160156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical recommendations for using ctDNA in clinical decision making.
    Cohen SA; Liu MC; Aleshin A
    Nature; 2023 Jul; 619(7969):259-268. PubMed ID: 37438589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.